Fungal Otitis Externa Market Share Expand To US$ 206.94 Million by 2028; CMI Revealing Industry Analysis To 2028

Global Fungal Otitis Externa Market, by Drug Type (Ear Drops (Clotrimazole, Fluconazole, and Acetic Acid (2%)), Oral Medications (Itraconazole and NSAIDS), Topical Medications, and Late Stage Pipeline Drugs),  by Fungus Type (Aspergillus and Candida), by Route of Administration (Otic, Oral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 169.40 Mn in 2021 and is expected to exhibit a CAGR of 2.9% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Get Your Sample Copy of the Fungal Otitis Externa Market Report 2021

Rising government initiatives for increasing awareness about serious fungal diseases is expected to drive the market growth over the forecast period. For instance, on the occasion of Fungal Disease Awareness Week on September 20-24, 2021, Centers for Disease Control and Prevention (CDC) and partners have organized this week to highlight the importance of recognizing serious fungal diseases early enough in the course of a patient’s illness to provide life-saving treatment.

Global Fungal Otitis Externa Market– Impact of Coronavirus (COVID-19) Pandemic on Clinical Trials and Drug Development

The COVID-19 pandemic has drastically affected clinical trials for fungal otitis externa. Several trials have paused enrollment and researchers are facing multiple challenges associated with setting up remote visits, and performing laboratory and other study assessments. For instance, according to a survey conducted by Medidata Solutions, Inc. (a U.S. based technology company, which develops and markets software as a service for clinical trials), on April 23, 2020, 63% of survey respondents reported that they stopped recruiting new patients for ongoing clinical trials and 43% of the respondents postponed their studies. The U.S. Food and Drug Administration (FDA) released guidelines on conducting clinical trials of medical products during the COVID-19 public health emergency in March 2020. The guidelines were further updated on July 02, 2020. The guidelines issued by the U.S. Food and Drug Administration (FDA) include general considerations to assist sponsors and researchers, which ensures the safety of trial participants, and compliance with good clinical practice (GCP) for the duration of the COVID-19 public health emergency. The appendix of the guidelines also provide answers to few general questions, which the U.S. Food and Drug Administration (FDA) received from various sponsors and researchers about conducting clinical trials during the COVID-19 public health emergency. Furthermore, healthcare facilities and researchers are adhering to the following safety measures for ongoing clinical trials. The healthcare providers obtain consent from patients over the phone or through video conferences. For instance, according to a survey conducted by Medidata Solutions, Inc., on April 23, 2020, 45% respondents opted for virtual/telemedicine for consultancy. The patient receives a phone call for screening of COVID-19 symptoms before the scheduled in-person visits.

 Browse 51 Market Data Tables and 36 Figures spread through 166 Pages and in-depth TOC on “Global Fungal Otitis Externa Market”- Forecast to 2028, Global Fungal Otitis Externa Market, by Drug Type (Ear Drops (Clotrimazole, Fluconazole, and Acetic Acid (2%)), Oral Medications (Itraconazole and NSAIDS), Topical Medications, and Late Stage Pipeline Drugs),  by Fungus Type (Aspergillus and Candida), by Route of Administration (Otic, Oral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),  and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),

To know the latest trends and insights prevalent in this market press release

Increasing prevalence of fungal otitis externa is expected to lead to high demand for various treatment therapy. According to the article published in the National Center for Biotechnology Information in March 2019, the lifetime prevalence rate of fungal otitis externa is estimated at 10%.

Key Takeaways of the Global Fungal Otitis Externa Market:

• The global fungal otitis externa market is expected to exhibit a CAGR of 2.9 % during the forecast period owing to increasing number of patients suffering from fungal otitis externa are expected to drive growth of the market over the forecast period. For instance, according to an article of American Academy of Family Physicians, the chronic form of otitis externa is commonly of a fungal or allergic origin or is the manifestation of dermatitides. It attacks three to five percent of the population. One–four acute otitis externa is unilateral in 90% of patients, it peaks in persons seven to 12 years of age, declines after 50 years of age, and often is associated with high humidity, warmer temperatures, swimming, local trauma, and hearing aid or hearing protector use.
• On the basis of distribution channel, retail pharmacies segment is estimated to exhibit a higher CAGR in the global fungal otitis externa market over forecast period. Retail pharmacies segment accounts for a significant market share, owing to patients’ preference for retail pharmacies, as well as the increasing number of retail or independent pharmacies across the globe. For instance, according to PLOS Journal’s August 2017 findings, independent pharmacies in the U.S. increased from 22,737 in 2007 to 23,596 in 2015, which witnessed a growth of 3.8%.
• In terms of route of administration, otic segment is estimated to hold a dominant position in the global fungal otitis externa market in 2021. Advantages of otic route include it is used to administer higher concentration of antibiotic to the site of infection also the otic medications are usually less expensive than comparable systemic medications. Thus, unique advantages of otic drugs are expected to drive the segment growth over the forecast period.
• Among regions, Asia Pacific is estimated to exhibit higher CAGR in the global fungal otitis externa market over the forecast period. Asia Pacific is expected to witness significant growth in geriatric population in coming years, and this group of population is more susceptible to chronic infections such as fungal otitis externa. This factor is expected to drive growth of the fungal otitis externa market during the forecast period. For instance, according to the United Nations data, one in four people in Asia and the Pacific will be over 60 years old by 2050. The population of older people (aged over 60) in the region will triple between 2010 and 2050, reaching close to 1.3 billion people in the region.
• Key players operating in the global fungal otitis externa market include Novartis, Bayer AG,  Sanofi,  GlaxoSmithKline plc.,  AbbVie,  Par Pharmaceutical, Inc.,  Hi-Tech Pharma,  Actavis Mid-Atlantic,  Hill Dermaceuticals Inc,  NuLife Pharmaceuticals,  Glenmark Pharmaceuticals Limited,  Pfizer Inc.,   Janssen Pharmaceutical,  McNeil Consumer Healthcare,  Mylan N.V.,  and, Salvat Laboratories

Buy This Full Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/4548

Reasons to Purchase this Report

• Current and future of global Fungal Otitis Externa market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players

“Limited Time Offer”

Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
We also offer 15% FREE Report customization.

Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/4548

Major Point Answered in Fungal Otitis Externa Market Research Study are: –

• What will the market growth rate, Overview and Analysis by Type of Fungal Otitis Externa market in 2026?
• What are the key factors driving, Analysis by Applications and Countries Fungal Otitis Externa market?
• What are Dynamics, This Overview Includes Analysis of Scope, and price analysis of top Manufacturers Profiles of Fungal Otitis Externa market?
• Who are the Opportunities, Risk and Driving Force of Fungal Otitis Externa market? Knows Upstream Raw Materials Sourcing and Downstream Buyers
• Who are the key vendors in Fungal Otitis Externa market space? Business Overview by Type, Applications, Gross Margin and Market Share
• What are the Fungal Otitis Externa market opportunities and threats faced by the vendors in the market?

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837